GT719 Injection for Moderate to Severe Refractory Autoimmune Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

GT719 Injection for Moderate to Severe Refractory Autoimmune Disease — Stella

Recruiting

Back to Auto Immune Disease trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

Affiliated Hospital of Nantong University, Nantong, Jiangsu

Key details

Phase

Very early testing

Sponsor

Grit Biotechnology

Collaborators

Affiliated Hospital of Nantong University

Enrollment target

~30 participants

Started

October 2025

Primary completion

August 2028

Age range

18 Years – 65 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov